Clinical prospective study of Gallium 68 (68Ga)-labeled fibroblast-activation protein inhibitor PET/CT in the diagnosis of biliary tract carcinoma

被引:13
|
作者
Li, Jinghua [1 ,2 ]
Xu, Kui [3 ]
Guo, Deliang [1 ,2 ]
Liao, Bo [1 ,2 ]
Zhu, Qian [1 ,2 ]
Wang, Haitao [1 ,2 ]
Jiang, Yaqun [2 ,3 ]
Wu, Dongde [4 ]
Xia, Xigang [5 ]
Jiang, Ping [1 ,2 ]
Tang, Shengli [1 ,2 ]
Yang, Zhiyong [1 ,2 ]
He, Yueming [1 ,2 ]
Zhang, Zhonglin [1 ,2 ]
He, Yong [2 ,3 ]
Yuan, Yufeng [1 ,2 ,6 ]
机构
[1] Wuhan Univ, Dept Hepatobiliary & Pancreat Surg, Zhongnan Hosp, Wuhan, Hubei, Peoples R China
[2] Clin Med Res Ctr Minimally Invas Procedure Hepatob, Wuhan, Hubei, Peoples R China
[3] Wuhan Univ, Dept Nucl Med, Zhongnan Hosp, Wuhan, Hubei, Peoples R China
[4] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Hepatobiliary & Pancreat Surg, Wuhan, Hubei, Peoples R China
[5] Jingzhou Cent Hosp, Dept Hepatobiliary Surg, Jingzhou, Hubei, Peoples R China
[6] Wuhan Univ, TaiKang Ctr Life & Med Sci, Wuhan, Hubei, Peoples R China
关键词
Fibroblast activation protein; FAPI; PET/CT; Biliary tract carcinoma; CANCER-ASSOCIATED FIBROBLASTS; F-18-FDG; MANAGEMENT;
D O I
10.1007/s00259-023-06137-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PurposeThis study is to investigate the [Ga-68]Ga-DOTA-FAPI PET/CT diagnosis performance in biliary tract carcinoma (BTC) and analyze the association between [Ga-68]Ga-DOTA-FAPI PET/CT and clinical indexes. Methods A prospective study (NCT 05264688) was performed between January 2022 and July 2022. Fifty participants were scanned using [Ga-68]Ga-DOTA-FAPI and [F-18]FDG PET/CT and acquired pathological tissue. We employed the Wilcoxon signed-rank test to compare the uptake of [Ga-68]Ga-DOTA-FAPI and [F-18]FDG, and the McNemar test was used to compare the diagnostic efficacy between the two tracers. Spearman or Pearson correlation was used to assess the association between [(68) Ga]Ga-DOTA-FAPI PET/CT and clinical indexes. Results In total, 47 participants (mean age 59.09 +/- 10.98 [range 33-80 years]) were evaluated. The [Ga-68]Ga-DOTA-FAPI detection rate was greater than [F-18]FDG in primary tumors (97.62% vs. 85.71%), nodal metastases (90.05% vs. 87.06%), and distant metastases (100% vs. 83.67%). The uptake of [Ga-68]Ga-DOTA-FAPI was higher than [F-18]FDG in primary lesions (intrahepatic cholangiocarcinoma, 18.95 +/- 7.47 vs. 11.86 +/- 0.70, p = 0.001; extrahepatic cholangiocarcinoma, 14.57 +/- 6.16 vs. 8.80 +/- 4.74, p = 0.004), abdomen and pelvic cavity nodal metastases (6.91 +/- 6.56 vs. 3.94 +/- 2.83, p < 0.001), and distant metastases (pleural, peritoneum, omentum, and mesentery, 6.37 +/- 4.21 vs. 4.50 +/- 1.96, p = 0.01; bone, 12.15 +/- 6.43 vs. 7.51 +/- 4.54, p = 0.008). There was a significant correlation between [Ga-68]Ga-DOTA-FAPI uptake and fibroblast-activation protein (FAP) expression (Spearman r = 0.432, p = 0.009), carcinoembryonic antigen (CEA) (Pearson r = 0.364, p = 0.012), and platelet (PLT) (Pearson r = 0.35, p = 0.016). Meanwhile, a significant relationship between [Ga-68]Ga-DOTA-FAPI metabolic tumor volume and carbohydrate antigen199 (CA199) (Pearson r = 0.436, p = 0.002) was confirmed. Conclusion [Ga-68]Ga-DOTA-FAPI had a higher uptake and sensitivity than [F-18]FDG in the diagnosis of BTC primary and metastatic lesions. The correlation between [Ga-68]Ga-DOTA-FAPI PET/CT indexes and FAP expression, CEA, PLT, and CA199 were confirmed.
引用
收藏
页码:2152 / 2166
页数:15
相关论文
共 47 条
  • [21] 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
    Lanzafame, Helena
    Mavroeidi, Ilektra A.
    Pabst, Kim M.
    Desaulniers, Melanie
    Ingenwerth, Marc
    Hirmas, Nader
    Kessler, Lukas
    Nader, Michael
    Bartel, Timo
    Leyser, Stephan
    Barbato, Francesco
    Schuler, Martin
    Bauer, Sebastian
    Siveke, Jens T.
    Herrmann, Ken
    Hamacher, Rainer
    Fendler, Wolfgang P.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (06) : 880 - 887
  • [22] Sentinel lymph node detection in thyroid carcinoma using [68Ga] Ga-tilmanocept PET/CT: a proof-of-concept study
    de Vries, Lisa H.
    Lodewijk, Lutske
    Ververs, Tessa
    Poot, Alex J.
    van Rooij, Rob
    Brosens, Lodewijk A. A.
    de Krijger, Ronald R.
    Rinkes, Inne H. M. Borel
    Vriens, Menno R.
    de Keizer, Bart
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (02) : 512 - 520
  • [23] Prognostic value of fibroblast activation protein expressing tumor volume calculated from [68 Ga]Ga-FAPI PET/CT in patients with esophageal squamous cell carcinoma
    Liang Zhao
    Yizhen Pang
    Shanyu Chen
    Jianhao Chen
    Yimin Li
    Yifeng Yu
    Chunbin Huang
    Long Sun
    Hua Wu
    Haojun Chen
    Qin Lin
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 593 - 601
  • [24] Prognostic value of fibroblast activation protein expressing tumor volume calculated from [68 Ga]Ga-FAPI PET/CT in patients with esophageal squamous cell carcinoma
    Zhao, Liang
    Pang, Yizhen
    Chen, Shanyu
    Chen, Jianhao
    Li, Yimin
    Yu, Yifeng
    Huang, Chunbin
    Sun, Long
    Wu, Hua
    Chen, Haojun
    Lin, Qin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (02) : 593 - 601
  • [25] 68Ga-Labeled Prostate-Specific Membrane Antigen Is a Novel PET/CT Tracer for Imaging of Hepatocellular Carcinoma: A Prospective Pilot Study
    Kesler, Mikhail
    Levine, Charles
    Hershkovitz, Dov
    Mishani, Eyal
    Menachem, Yoram
    Lerman, Hedva
    Zohar, Yaniv
    Shibolet, Oren
    Even-Sapir, Einat
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (02) : 185 - 191
  • [26] Fibroblast Activation Protein-Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT
    Luo, Yaping
    Pan, Qingqing
    Yang, Huaxia
    Peng, Linyi
    Zhang, Wen
    Li, Fang
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (02) : 266 - 271
  • [27] Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT
    Wei Guo
    Yizhen Pang
    Lanlin Yao
    Liang Zhao
    Chunlei Fan
    Jingpeng Ke
    Ping Guo
    Bing Hao
    Hao Fu
    Chengrong Xie
    Qin Lin
    Hua Wu
    Long Sun
    Haojun Chen
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 1604 - 1617
  • [28] Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [18F]F-FDG PET/CT in Patients with Liver Malignancies
    Siripongsatian, Dheeratama
    Promteangtrong, Chetsadaporn
    Kunawudhi, Anchisa
    Kiatkittikul, Peerapon
    Boonkawin, Natphimol
    Chinnanthachai, Chatchawarin
    Jantarato, Attapon
    Chotipanich, Chanisa
    MOLECULAR IMAGING AND BIOLOGY, 2022, 24 (05) : 818 - 829
  • [29] Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial
    Rasinski, Pawel
    af Buren, Siri
    Holstensson, Maria
    Nilsson, Ted
    Loizou, Louiza
    Tran, Thuy A.
    Sparrelid, Ernesto
    Lohr, J. Matthias
    Axelsson, Rimma
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (08) : 1232 - 1237
  • [30] Head-to-Head Comparison of SSTR Antagonist [68Ga]Ga-DATA5m-LM4 with SSTR Agonist [68Ga]Ga-DOTANOC PET/CT in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Imaging Study
    Viswanathan, Rahul
    Ballal, Sanjana
    Yadav, Madhav P.
    Roesch, Frank
    Sheokand, Parvind
    Satapathy, Swayamjeet
    Tripathi, Madhavi
    Agarwal, Shipra
    Moon, Euy Sung
    Bal, Chandrasekhar
    PHARMACEUTICALS, 2024, 17 (03)